SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to ...
Boundless Bio’s announcement earlier this month of plans to go public was a sign that the biotech IPO window hadn’t slammed shut after a flurry of offerings at the start of the year. Now, the company ...
The Boundless team has grown to 28 employees in the company’s first two years. (Boundless Photo) In the two years since it launched, Boundless has become the top destination for immigrants applying ...
Discontinuing current monotherapy and combination arms of BBI-355 in POTENTIATE clinical trial. Plans to evaluate BBI-355 and BBI-825 as a combination therapy in the POTENTIATE clinical trial, ...
Targeted therapies and immunotherapies offer new treatment options for more types of cancer, but these drugs are less helpful when tumors produce multiple copies of a gene. This gene amplification ...
Boundless Publishing Group and its imprint Neem Tree Press entered liquidation and stopped conducting business as of Friday, ending a months-long effort to rescue the assets of failed crowdfunding ...
Editor’s note: This is part of a series profiling six of the Seattle region’s “Uncommon Thinkers”: inventors, scientists, technologists and entrepreneurs transforming industries and driving positive ...
I Am Boundless, Inc. launched its #BoundlesslyBeautiful campaign to promote inclusivity and to challenge societal beauty standards. The event aimed to empower the women, to give them a voice and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results